Literature DB >> 21954479

Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy.

Monika Ferlitsch1, Karoline Reinhart, Sibylle Pramhas, Caspar Wiener, Orsolya Gal, Christina Bannert, Michaela Hassler, Karin Kozbial, Daniela Dunkler, Michael Trauner, Werner Weiss.   

Abstract

CONTEXT: Although some studies have shown that men are at greater age-specific risk for advanced colorectal neoplasia than women, the age for referring patients to screening colonoscopy is independent of sex and usually recommended to be 50 years.
OBJECTIVE: To determine and compare the prevalence and number needed to screen (NNS) for adenomas, advanced adenomas (AAs), and colorectal carcinomas (CRCs) for different age groups in men and women. DESIGN, SETTING, AND PATIENTS: Cohort study of 44,350 participants in a national screening colonoscopy program over a 4-year period (2007 to 2010) in Austria. MAIN OUTCOME MEASURES: Prevalence and NNS of adenomas, AAs, and CRCs in different age groups for men and women.
RESULTS: The median ages were 60.7 years (interquartile range [IQR], 54.5-67.5 years) for women and 60.6 years (IQR, 54.3-67.6 years) for men, and the sex ratio was nearly identical (51.0% [22,598] vs 49.0% [21,572]). Adenomas were found in 19.7% of individuals screened (95% CI, 19.3%-20.1%; n = 8743), AAs in 6.3% (95% CI, 6.1%-6.5%; n = 2781), and CRCs in 1.1% (95% CI, 1.0%-1.2%; n = 491); NNS were 5.1 (95% CI, 5.0-5.2), 15.9 (95% CI, 15.4-16.5), and 90.9 (95% CI, 83.3-100.0), respectively. Male sex was significantly associated with a higher prevalence of adenomas (24.9% [95% CI, 24.3%-25.4%] vs 14.8% [95% CI, 14.3%-15.2%]; P < .001; unadjusted odds ratio [OR], 1.9 [95% CI, 1.8-2.0]), AAs (8.0% [95% CI, 7.6%-8.3%] vs 4.7% [95% CI, 4.4%-4.9%]; P < .001; unadjusted OR, 1.8 [95% CI, 1.6-1.9]), and CRCs (1.5% [95% CI, 1.3%-1.7%] vs 0.7% [95% CI, 0.6%-0.9%]; P < .001; unadjusted OR, 2.1 [95% CI, 1.7-2.5]). The prevalence of AAs in 50- to 54-year-old individuals was 5.0% (95% CI, 4.4%-5.6%) in men but 2.9% (95% CI, 2.5%-3.4%) in women (adjusted P = .001); the NNS in men was 20 (95% CI, 17.8-22.6) vs 34 in women (95% CI, 29.1-40; adjusted P = .001). There was no statistical significance between the prevalence and NNS of AAs in men aged 45 to 49 years compared with women aged 55 to 59 years (3.8% [95% CI, 2.3%-6.1%] vs 3.9% [95% CI, 3.3%-4.5%] and 26.1 [95% CI, 16.5-44.4] vs 26 [95% CI, 22.5-30.2]; P = .99).
CONCLUSION: Among a cohort of Austrian individuals undergoing screening colonoscopy, the prevalence and NNS of AAs were comparable between men aged 45 to 49 years and women aged 55 to 59 years.

Entities:  

Mesh:

Year:  2011        PMID: 21954479     DOI: 10.1001/jama.2011.1362

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  77 in total

1.  Sex disparity in colonic adenomagenesis involves promotion by male hormones, not protection by female hormones.

Authors:  James M Amos-Landgraf; Jarom Heijmans; Mattheus C B Wielenga; Elisa Dunkin; Kathy J Krentz; Linda Clipson; Antwan G Ederveen; Patrick G Groothuis; Sietse Mosselman; Vanesa Muncan; Daniel W Hommes; Alexandra Shedlovsky; William F Dove; Gijs R van den Brink
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Clinical Practice Patterns Suggest Female Patients Prefer Female Endoscopists.

Authors:  Jessica Davis; Brandon Rieders; Marie L Borum
Journal:  Dig Dis Sci       Date:  2015-08-28       Impact factor: 3.199

3.  Should Screening Colonoscopy Be Offered From Age 50?

Authors:  Hermann Brenner; Nadine Zwink; Leopold Ludwig; Michael Hoffmeister
Journal:  Dtsch Arztebl Int       Date:  2017-02-10       Impact factor: 5.594

4.  Different risk factors for advanced colorectal neoplasm in young adults.

Authors:  Ji Yeon Kim; Yoon Suk Jung; Jung Ho Park; Hong Joo Kim; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Kyu Yong Choi; Dong Il Park
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 5.  Do recent epidemiologic observations impact who and how we should screen for CRC?

Authors:  Ethan Bortniker; Joseph C Anderson
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

6.  Learning to be More Positive About FIT.

Authors:  Douglas J Robertson
Journal:  Am J Gastroenterol       Date:  2018-11-05       Impact factor: 10.864

7.  Raloxifene and antiestrogenic gonadorelin inhibits intestinal tumorigenesis by modulating immune cells and decreasing stem-like cells.

Authors:  Naveena B Janakiram; Altaf Mohammed; Misty Brewer; Taylor Bryant; Laura Biddick; Stan Lightfoot; Gopal Pathuri; Hariprasad Gali; Chinthalapally V Rao
Journal:  Cancer Prev Res (Phila)       Date:  2014-01-15

8.  The potential of imaging techniques as a screening tool for colorectal cancer: a cost-effectiveness analysis.

Authors:  Marjolein J E Greuter; Johannes Berkhof; Remond J A Fijneman; Erhan Demirel; Jie-Bin Lew; Gerrit A Meijer; Jaap Stoker; Veerle M H Coupé
Journal:  Br J Radiol       Date:  2016-05-19       Impact factor: 3.039

9.  Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia.

Authors:  Thomas F Imperiale; Elizabeth A Glowinski; Ching Lin-Cooper; David F Ransohoff
Journal:  Am J Med       Date:  2012-10-09       Impact factor: 4.965

10.  Quality Matters: Improving the Quality of Care for Patients With Complex Colorectal Polyps.

Authors:  Ian Grimm; Anne F Peery; Tonya Kaltenbach; Seth D Crockett
Journal:  Am J Gastroenterol       Date:  2017-11-07       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.